Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Intelligent Bio Solutions's enterprise value is $-0.54 Mil.
Intelligent Bio Solutions's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-10.37 Mil. Therefore, Intelligent Bio Solutions's EV-to-EBITDA for today is 0.05.
The historical rank and industry rank for Intelligent Bio Solutions's EV-to-EBITDA or its related term are showing as below:
INBS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.18 Med: -0.29 Max: 0.55
Current: 0.05
During the past 9 years, the highest EV-to-EBITDA of Intelligent Bio Solutions was 0.55. The lowest was -3.18. And the median was -0.29.
INBS's EV-to-EBITDA is ranked better than 98.84% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.76
vs INBS: 0.05
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Intelligent Bio Solutions (NAS:INBS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Intelligent Bio Solutions's PE Ratio (TTM) for today is calculated as:
Intelligent Bio Solutions's share price for today is $1.97.
Intelligent Bio Solutions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.200.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Intelligent Bio Solutions's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intelligent Bio Solutions EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Intelligent Bio Solutions's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Intelligent Bio Solutions's EV-to-EBITDA falls into.
Intelligent Bio Solutions's current Enterprise Value is $-0.54 Mil.
Intelligent Bio Solutions's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intelligent Bio Solutions (INBS) has a EV-to-EBITDA of 0.05 as of Aug. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Intelligent Bio Solutions. According to the industry distribution chart, Intelligent Bio Solutions ranks #6 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 1.2%.
Is Intelligent Bio Solutions' EV-to-EBITDA too high?
Intelligent Bio Solutions' current EV-to-EBITDA is 0.05. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.76. Intelligent Bio Solutions' value of 0.05 is 99.7% below this industry median. Based on the distribution chart, Intelligent Bio Solutions ranks #6 out of 516 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Intelligent Bio Solutions has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Intelligent Bio Solutions' EV-to-EBITDA compare to RMSL and USAQ?
According to the Medical Devices & Instruments industry distribution chart, Intelligent Bio Solutions ranks #6 out of 516 companies for EV-to-EBITDA. This places Intelligent Bio Solutions in the top 1% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.76. Intelligent Bio Solutions' value of 0.05 is 99.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.76, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intelligent Bio Solutions's current EV-to-EBITDA of 0.05 is 99.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Intelligent Bio Solutions. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intelligent Bio Solutions's current EV-to-EBITDA is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intelligent Bio Solutions stock overvalued right now?
Based on GuruFocus' analysis, Intelligent Bio Solutions (INBS) is currently considered Possible Value Trap. The stock's GF Value™ is $3.93, compared to a current price of $1.97 — trading 49.9% below its estimated fair value. The current EV-to-EBITDA is 0.05 and 99.7% below the Medical Devices & Instruments industry median of 14.76. Intelligent Bio Solutions' overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Intelligent Bio Solutions (INBS), the current EV-to-EBITDA is 0.05 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intelligent Bio Solutions (INBS) Overvalued in 2026?
Based on GuruFocus' analysis, Intelligent Bio Solutions stock appears to be undervalued.
The current stock price of $1.97 is trading 49.9% below its estimated GF Value™ of $3.93.
GuruFocus considers Intelligent Bio Solutions to be Possible Value Trap.
Key valuation signals for INBS:
EV-to-EBITDA: 0.05
GF Value™: $3.93 vs. price of $1.97 (49.9% below fair value)
Industry Position: 99.7% below the Medical Devices & Instruments median (#6 of 516)
No single metric tells the full story. See the INBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
41GF Score
Get the complete analysis for INBS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBS has been successfully added to your 
